If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
== GBS colonization == GBS is a normal component of the intestinal and vaginal microbiota in some people; GBS is an asymptomatic (presenting no symptoms) colonizer of the gastrointestinal tract and vagina in up to 30% of otherwise healthy adults, including pregnant women. GBS colonization may be permanent, intermittent, or temporary. In different studies, the GBS vaginal colonization rate ranges from 0% to 36%, with most studies reporting colonization rates in sexually active women over 20%. It has been estimated that maternal GBS colonization worldwide is 18%, with regional variation from 11% to 35%. These variations in the reported prevalence of asymptomatic GBS colonization may be attributable to the detection methods used and differences in study populations.
On 18 March 2021, German regional leaders including State Premiers and the mayor of Berlin called for the swift approval of the Russian vaccine by the European Medicines Agency to counteract the acute shortages of effective vaccines in Europe. German medical experts have recommended its approval also, and consider the Sputnik Vaccine "clever" and "highly safe". On 19 March 2021, the Philippine Food and Drug Administration granted emergency use authorization for Sputnik V, the fourth COVID-19 vaccine to be given authorization. The Philippine government planned to buy 20 million doses of the vaccine. On 12 April 2021, India approved the use of Sputnik V vaccine for emergency use against COVID-19 based on strong immunogenicity data. As of 12 April 2021, 62 countries had granted Sputnik V emergency use authorization. On 27 April 2021, Bangladesh approved the use of Sputnik V vaccine for emergency use. On 30 April 2021, Turkey and Albania approved the use of Sputnik V vaccine for emergency use.
===== Drug trafficking ===== 17 November 2013: Yong Vui Kong, a Malaysian found guilty of drug trafficking in 2007 and sentenced to death in 2008. He lost multiple appeals against his sentence to the Court of Appeal and President of Singapore. However, when changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 15 strokes of the cane. Yong was the first drug convict on death row to be spared the gallows since the 2013 law reforms. 6 January 2014: Subashkaran Pragasam, a Singaporean found guilty of trafficking heroin in 2008 and sentenced to death in 2012. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. 3 March 2014: Dinesh Pillai Reja Retnam, a Malaysian found guilty of trafficking heroin in 2009 and sentenced to death in 2011. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment on the grounds of diminished responsibility due to him suffering from depression when he committed the crime. 27 May 2014: Yip Mun Hei, a Singaporean convicted of trafficking heroin in 2008 and sentenced to death in 2009. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. He had an accomplice Leong Soy Yip (also sentenced to death) whose fate remains unknown.
==== Trigger (induction) ==== Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors (GPVI receptor and integrin α2β1) on the platelet. GPVI is associated with the Fc receptor gamma chain and leads via the activation of a tyrosine kinase cascade finally to the activation of PLC-gamma2 (PLCG2) and more calcium release. Tissue factor also binds to factor VII in the blood, which initiates the extrinsic coagulation cascade to increase thrombin production. Thrombin is a potent platelet activator, acting through Gq and G12. These are G protein-coupled receptors and they turn on calcium-mediated signaling pathways within the platelet, overcoming the baseline calcium efflux. Families of three G proteins (Gq, Gi, G12) operate together for full activation. Thrombin also promotes secondary fibrin-reinforcement of the platelet plug. Platelet activation in turn degranulates and releases factor V and fibrinogen, potentiating the coagulation cascade. Platelet plugging and coagulation occur simultaneously, with each inducing the other to form the final fibrin-crosslinked thrombus.
Sources: en.wikipedia.org
Freeze-casting can be applied to produce aligned porous structure from diverse building blocks including ceramics, polymers, biomacromolecules, graphene and carbon nanotubes. As long as there are particles that may be rejected by a progressing freezing front, a templated structure is possible. By controlling cooling gradients and the distribution of particles during freeze casting, using various physical means, the orientation of lamellae in obtained freeze cast structures can be controlled to provide improved performance in diverse applied materials. Munch et al. showed that it is possible to control the long-range arrangement and orientation of crystals normal to the growth direction by templating the nucleation surface. This technique works by providing lower energy nucleation sites to control the initial crystal growth and arrangement. The orientation of ice crystals can also be affected by applying electromagnetic fields as was demonstrated in 2010 by Tang et al. in 2012 by Porter et al., and in 2021 by Yin et al. Using specialized setups, researchers have been able to create radially aligned freeze-casts tailored for biomedical applications and filtration or gas separation applications. Inspired by nature, scientists have also been able to use coordinating chemicals and cryopreserved to create remarkably distinctive microstructural architectures.
== Births == 17 January - William Saunders, poet (died 1851) 1 February - Jane Williams (Ysgafell), writer (died 1885) 9 April - Theophilus Redwood, pharmacist (died 1892) 21 April - Sir George Cornewall Lewis, statesman (died 1863) date unknown Joseph Murray Ince, painter (died 1859) Harry Longueville Jones, archæologist, artist and Inspector of Schools for Wales (died 1870) David Pugh, politician (died 1890) probable - Thomas Rees (Twm Carnabwth), Rebecca rioter (died 1876)
subunit A single unit of a multi-unit compound or molecular aggregate; e.g. a monomer from which a larger polymer is composed (as with nucleotides in nucleic acids), or an individual polypeptide chain in a multi-chain protein, or an entire protein which participates alongside other proteins as part of a protein complex.
=== Mitigate carbon nanotube toxicity via physicochemical modulation === Length, diameter, and aggregation state: As-synthesized CNTs typically form large bundles or agglomerates, which are associated with increased cytotoxicity. Disaggregation into individualized CNTs and cutting length can mitigate toxicity. These modifications are commonly achieved through tip ultrasonication in the presence of surfactants or polymers, followed by ultracentrifugation to remove residual bundles and impurities. Such processing enhances dispersion, reduces rigidity, and improves biocompatibility. Single-type enrichment and classification: Heterogeneity in CNT materials contributes to inconsistent biological responses. Advanced sorting techniques, such as aqueous two-phase extraction, size-exclusion chromatography, and density gradient ultracentrifugation, can sort CNTs by specific parameters such as diameter, length, number of walls, and chirality. Purity enhancement: Post-synthesis purification techniques—such as mild oxidation, sonication in hydrogen peroxide or acetone, acid washing, and incandescent annealing—are employed to remove residual metal catalysts and carbonaceous byproducts. Surface modification: Non-covalent modification: Wrapping CNTs with biocompatible polymers such as single-stranded DNA (ssDNA), phospholipid–polyethylene glycol, or Pluronic F108 enhances solubility, colloidal stability, and biological compatibility without altering the intrinsic structure of the nanotubes.
Silver - Bar Gary William Adams, , Gatekeeper, Crown Estate, Windsor. Andrew John Buckland, , Jersey Herdsman, Royal Farms, Windsor. Neil Hepple Dodds, , Team Supervisor, Crown Estate, Windsor. Jose Manuel Lazarczuk, , Groundsman, Crown Estate Windsor. Silver Andrew David Basson, Office Assistant and Insignia Clerk, Royal Household. Gary Clarke, Fire Safety and Access Officer, Buckingham Palace. Edward Peter Evans, lately Divisional Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Malcolm Greenland, Castle Attendant, Windsor Castle. Helen Hitchcock, lately Coffee Shop Supervisor, Windsor Farm Shop. Isabel Lorna Laylo, Housekeeping Assistant, Kensington Palace. Matthew Simon Murphy, Senior Palace Attendant, Royal Household. Timothy James Rayson, Axe Keeper, The Honourable Corps of Gentlemen at Arms. Elisabeth Michelle Roberts, Helpdesk and Property Co-ordinator, Windsor Castle. Corporal of the Horse Kate Elizabeth Sandford, Royal Corps of Army Music, 30186649; Household Cavalry Band, on the occasion of the Coronation of Their Majesties The King and The Queen. James Richard Shaw, lately Personal Assistant to the Assistant Private Secretary to His Majesty The King. Fiona Ailsa Smith, lately Ranger, Balmoral Estate. John Sspelzini, Divisional Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Monica Jane Tandy, Warden, Windsor Castle. Vanessa Anne Wakeford, House Manager, Government House, Guernsey. Barry James Whearty, Painter and Decorator, Crown Estate, Windsor.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.